A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting · Phase 2 · NCT06769698
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
At a glance
- Research payments reported, 2025
- $12,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- FDC fianlimab+cemiplimab (drug), Cemiplimab (drug), Placebo (drug)
- Dates
- Started 2026-04-14; completion 2030-12-28
- Results posted
- Not yet
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The study is looking at several other research questions, including: * What side effects may happen from taking the …
From ClinicalTrials.gov, last updated 2026-10-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $12,500 in research payments for this study in 2025 (1 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Renovatio Clinical Consultants LLC $12,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.